HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sisson, J. C. Articles by Wieland, D. M. Search for Related Content PubMed PubMed Citation Articles by Sisson, J. C. Articles by Wieland, D. M.

Radiopharmaceutical Treatment of Malignant Pheochromocytoma

The University of Michigan Medical Center, Ann Arbor, Michigan

Correspondence: For reprints contact: James C. Sisson MD, Nuclear Medicine Division, University of Michigan Medical Center, Ann Arbor, MI 48109.

ABSTRACT

Apart from relieving effects of secreted catecholamines, treatments of malignant pheochromocytoma have achieved little success. When the radiopharmaceutical, meta-[¹³¹I]iodobenzylguanidine (I-131 MIBG), was found to concentrate in some malignant pheochromocytomas, we calculated that this agent could impart therapeutic doses of radiation to these tumors. We therefore treated five patients with two to four doses of I-131 MIBG prepared in high specific activity, 8–11 Ci/mmol. Individual doses were given at 3- to 10-mo intervals and in 97- to 197-mCi amounts. Two patients exhibited subjective and objective benefits. Their tumor declined in size (to 28% and 30% of original volumes) and in hormone secretion (to 50% or less of baseline rates). The other three patients manifested few symptoms before treatment and showed few or no objective improvement afterward. The tumors of the patients who responded to I-131 MIBG (a) appeared to be more rapidly growing, (b) received more cumulative rads, and (c) were more predominantly in soft tissues (in contrast to bone) than those in the patients who obtained little benefit. No toxic effects were encountered during the treatments, and only minor and temporary untoward responses were seen later.

This article has been cited by other articles:

				G. H. Hinkle, J. V. Dura, R. S. Morosco, and M. C. Nahata Extended stability of iobenguane under simulated clinical conditions Am. J. Health Syst. Pharm., January 15, 2008; 65(2): 142 - 144. [Abstract] [Full Text] [PDF]

				T. Scholz, G. Eisenhofer, K. Pacak, H. Dralle, and H. Lehnert Current Treatment of Malignant Pheochromocytoma J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1217 - 1225. [Abstract] [Full Text] [PDF]

				M. G. E. H. Lam, C. J. M. Lips, P. L. Jager, R. P. F. Dullaart, E. G. W. M. Lentjes, P. P. van Rijk, and J. M. H. de Klerk Repeated [131I]Metaiodobenzylguanidine Therapy in Two Patients with Malignant Pheochromocytoma J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5888 - 5895. [Abstract] [Full Text] [PDF]

				J. U. Kelly The Use of an Investigational Radiopharmaceutical in Neuroblastoma: A Nursing Perspective Journal of Pediatric Oncology Nursing, January 1, 1989; 6(4): 133 - 138. [Abstract] [PDF]